Sobi moves to acquire full control of Pint Pharma to expand Latin American rare disease platform

The transaction would give Sobi full ownership of a specialist commercialisation platform spanning seven Latin American markets, building on its $105 million investment in Pint Pharma in 2025.

Swedish Orphan Biovitrum (Sobi) is seeking to acquire the remaining shares of Pharma Investments, the parent company of Pint Pharma, giving it full ownership of the Latin American specialist pharmaceutical business following its $105 million investment for 19.9% of voting rights and 60% of economic rights in 2025.

The transaction would give Sobi direct control of a regional platform covering regulatory approval, market access and distribution of specialist medicines across seven Latin American markets, supporting its expansion in rare diseases, haematology and oncology.

Field	Content
Alert Type	Deal
Companies	Swedish Orphan Biovitrum (Sobi); Pint Pharma / Pharma Investments
Deal Type	Acquisition of remaining ownership interest
Asset or Company	Pharma Investments, parent company of Pint Pharma
Therapy Area(s)	Rare diseases; Haematology; Oncology
Deal Value	Consideration for the acquisition of the remaining shares has not been disclosed. In November 2025, Sobi paid $105 million for 19.9% of the voting rights and 60% of the economic rights in Pint Pharma; that amount relates to the earlier investment and is not the consideration for the current transaction. (Dealroom.co)
Geography	Latin America, including Brazil, Mexico, Argentina and Colombia
What Happened	Sobi is moving to acquire all remaining shares of Pharma Investments, the parent company of Pint Pharma, according to a transaction submitted to Brazil's competition authority Cade. The proposed acquisition builds on Sobi's 2025 investment, when it acquired 19.9% of the voting rights and 60% of the economic rights for $105 million. Completion would give Sobi full control of Pint Pharma, which operates across seven Latin American markets. The transaction remains subject to the relevant review and has not yet been presented as completed. (Dealroom.co)
Why It Matters	Full ownership would give Sobi direct control of an established Latin American platform for regulatory approval, market access and distribution of specialist medicines. This could provide Sobi with greater control over launches and commercialisation across markets where navigating country-specific regulatory and access requirements can be important for rare disease and speciality medicines. (Dealroom.co)
Supporting Context	Sobi and Pint Pharma have maintained a commercial relationship since 2021. The companies expanded that relationship in 2025 when Sobi invested $105 million in Pint Pharma, describing the business as a launch platform for Sobi medicines in Brazil and the wider Latin American region. (Sobi)
Strategic Rationale	Sobi would move from holding a majority economic interest but minority voting position to full ownership, giving it direct control of Pint Pharma's regional infrastructure and expertise. The transaction therefore deepens an existing partnership rather than representing Sobi's entry into an entirely new commercial relationship. (Dealroom.co)
Potential Impact	Full ownership could allow Sobi to use Pint Pharma more extensively as a regional launch and commercialisation platform for its specialist portfolio. The eventual impact will depend on transaction completion and Sobi's subsequent decisions regarding which products are introduced through the platform.
Key Takeaway	Full ownership of Pint Pharma would give Sobi direct control of a seven-market Latin American platform for launching and commercialising rare disease and speciality medicines.
What to Watch	Review by Brazil's Cade, completion of the acquisition, disclosure of the purchase consideration and Sobi's plans for integrating Pint Pharma into its Latin American commercial operations. (Dealroom.co)
Primary Source	Brazilian competition filing (Cade); transaction details reported by Dealroom.co based on InvestNews
Relevant Date	7 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com